Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT06980623
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.

Key Dates

Start date
Jan 1, 2025
Status verified
May 2026
Primary completion
Nov 30, 2025
Completion
Oct 1, 2026

Study Design

Enrollment
26,000 participants (estimated)

Arms

  • Arm: Tirzepatide
    Patients who initiated tirzepatide with no use in the prior 180 days
  • Arm: Semaglutide
    Patients who initiate semaglutide with no use in the prior 180 days

Primary Outcome Measure

Hospitalization for heart failure and all-cause mortality [ Time Frame: From treatment initiation to end of follow up, up to 48 months. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02120-

Find similar trials in Boston, MA

By condition
Heart failureType 2 diabetes
By specialty
CardiologyHeart diseaseEndocrinologyMetabolic healthWeight loss
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies